Transformation of myelodysplastic syndrome to mixed phenotype acute leukaemia [0.03%]
向混合表型急性白血病转化的骨髓增生异常综合征
Louis Do,John Giannoutsos
Louis Do
Toru Kawakami,Hideyuki Nakazawa,Fumihiro Ishida
Toru Kawakami
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP [0.03%]
利妥昔单抗维持治疗可显著降低初治患者R-CHOP治疗后早期滤泡淋巴瘤进展风险
Vít Procházka,David Belada,Andrea Janíková et al.
Vít Procházka et al.
Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years si...
Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation [0.03%]
后置式环磷酰胺替换苯达莫斯汀的造血干细胞移植临床I期试验
Emmanuel Katsanis,Keri Maher,Denise J Roe et al.
Emmanuel Katsanis et al.
We have initiated a single center phase I study in patients with hematologic malignancies progressively substituting day +4 posttransplant cyclophosphamide (PT-CY) with bendamustine (PT-BEN) following myeloablative conditioning (MAC) and T-...
Luspatercept-induced reduction in transfusion requirement in α-thalassemia [0.03%]
Luspatercept诱导的α地中海贫血输血需求降低效应
Nicholas Jackson,Shasha Khairullah,Ping Chong Bee
Nicholas Jackson
Case Reports
EJHaem. 2020 Jul 9;1(1):297-299. DOI:10.1002/jha2.54 2020
Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials [0.03%]
达托珠单抗联合方案治疗多发性骨髓瘤疗效的III期随机临床试验合并分析
Thura W Htut,Kyaw Z Thein,Alastair Lawrie et al.
Thura W Htut et al.
The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RC...
Systemic mastocytosis with an associated hematological neoplasms: One or two entities? [0.03%]
系统性肥大细胞增生伴发血液系统肿瘤：一种还是两种疾病？
Linet Njue,Naomi Porret,Michaela Fux et al.
Linet Njue et al.
A meta-analysis of toxicities related to hydroxycarbamide dosing strategies [0.03%]
关于羟基脲给药方案相关的毒性的meta分析
Joacy G Mathias,Vikki G Nolan,Meghan Meadows-Taylor et al.
Joacy G Mathias et al.
Due to fear of short-term toxicities, there is nonconsensus of hydroxycarbamide dosing strategy (escalated vs fixed-dosing methods), which contributes to its suboptimal use. We performed a meta-analysis to summarize the incidence rates of t...
Nordberg Nørgaard Jakob,Bugge Askeland Frida,Tjønnfjord Geir et al.
Nordberg Nørgaard Jakob et al.